Company: LBRX
Filing Date: 2025-07-23
Form Type: DRS/A
Source: 0000950123-25-006557
Chunk: 140

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-07-23
Form: DRS/A
Chunk 140
---
 upon the exercise of common                                                                                                   
 stock warrants outstanding as of     , with an exercise price of $0.01 per share, as more fully described in the section titled “Description of Capital Stock—Warrants—Maxim Warrants;” |

| • |     | shares of our common stock issuable upon the exercise of common stock warrants                                                                                     
 outstanding as of     , with an exercise price of $0.01 per share, as more fully described in the section titled “Description of Capital Stock—Warrants—Series B-1 
 Warrants;”                                                                                                                                                         |

| • |     | shares of our common stock issuable upon the exercise of common stock warrants                                                                                                  
 outstanding as of     , with an exercise price of $1.50 per share, as more fully described in the section titled “Description of Capital Stock—Warrants—New Series B Warrants;” |

| • |     | shares of common stock reserved for future issuance under our 2025 Plan, which became                                                                                                                                                                     
 effective upon the execution and delivery of the underwriting agreement for this offering, as well as any future automatic annual increases in the number of shares of common stock reserved for issuance under our 2025 Plan, as more fully described in 
 the section titled “Executive Compensation—Equity Benefit Plans;” and                                                                                                                                                                                     |

| • |     | shares of common stock reserved for future issuance under our ESPP, which became                                                                                                                                                                         
 effective upon the execution and delivery of the underwriting agreement for this offering, as well as any future automatic annual increases in the number of shares of common stock reserved for future issuance under our ESPP, as more fully described 
 in the section titled “Executive Compensation—Equity Benefit Plans.”                                                                                                                                                                                     |

93

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes appearing elsewhere in this prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this prospectus, including information with respect to our current plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the “Risk Factors” section of this prospectus, our actual results could differ materially from the results described in or